{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:51:47Z","timestamp":1788292307504,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T17:39:07Z","timestamp":1558719547000},"page":"587-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and\/or BCL6 Rearrangements"],"prefix":"10.1016","volume":"33","author":[{"given":"Rami","family":"Alsharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.hoc.2019.04.001_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"197","key":"10.1016\/j.hoc.2019.04.001_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A\u00a0sarcoma involving the jaws in African children","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.001_bib3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: clues to the pathogenesis of Burkitt lymphoma","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J\u00a0Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2019.04.001_bib4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2019.04.001_bib5","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and\/or biology?","volume":"116","author":"Guech-Ongey","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2019.04.001_bib6","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2019.04.001_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/8.suppl_2.S101","article-title":"Bcl-6 protein expression in normal and neoplastic lymphoid tissues","volume":"8","author":"Falini","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2019.04.001_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2007.1.277","article-title":"Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy","volume":"1","author":"Kelly","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"24","key":"10.1016\/j.hoc.2019.04.001_bib9","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.001_bib10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2019.04.001_bib11","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2010-08-301556","article-title":"Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes","volume":"117","author":"Piccaluga","year":"2011","journal-title":"Blood"},{"issue":"7418","key":"10.1016\/j.hoc.2019.04.001_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.001_bib13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.001_bib14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.001_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737140.2014.866042","article-title":"Improving the accuracy in prognosis for Burkitt lymphoma patients","volume":"14","author":"Castillo","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.001_bib16","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.001_bib17","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"Wasterlid","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.001_bib18","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3109\/10428194.2011.593274","article-title":"Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study","volume":"52","author":"Wasterlid","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2019.04.001_bib19","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.001_bib20","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A\u00a0prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.001_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JOP.18.00148","article-title":"Approach to the diagnosis and treatment of adult Burkitt's lymphoma","volume":"14","author":"Dunleavy","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.001_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.1983.1.11.677","article-title":"Central nervous system involvement in American Burkitt's lymphoma","volume":"1","author":"Sariban","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.001_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2019.04.001_bib24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.001_bib25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.hoc.2019.04.001_bib26","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.001_bib27","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.001_bib28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.hoc.2016.07.009","article-title":"Update on Burkitt lymphoma","volume":"30","author":"Dunleavy","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10036","key":"10.1016\/j.hoc.2019.04.001_bib29","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.hoc.2019.04.001_bib30","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.001_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.001_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.hoc.2019.04.001_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.hoc.2019.04.001_bib34","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.001_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMc1806191","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"379","author":"Wright","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2019.04.001_bib36","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.001_bib37","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.001_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.001_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.001_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.14282","article-title":"Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable","volume":"175","author":"Landsburg","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.001_bib41","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","article-title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial","volume":"28","author":"Kuhnl","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.001_bib42","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2019.04.001_bib43","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.001_bib44","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.001_bib45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10428194.2017.1339882","article-title":"MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R","volume":"59","author":"Lai","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"10.1016\/j.hoc.2019.04.001_bib46","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:10:34Z","timestamp":1760184634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819300528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889858819300528"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and\/or BCL6 Rearrangements","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}